Novare Capital Management’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$28.1M Sell
115,100
-4,807
-4% -$1.12M 2.23% 11
2025
Q4
$24.8M Sell
119,907
-1,541
-1% -$305K 1.86% 14
2025
Q3
$22.5M Sell
121,448
-37
-0% -$6.34K 1.71% 14
2025
Q2
$18.6M Buy
121,485
+1,492
+1% +$229K 1.51% 17
2025
Q1
$19.9M Sell
119,993
-1,102
-0.9% -$172K 1.74% 17
2024
Q4
$17.5M Sell
121,095
-1,210
-1% -$188K 1.47% 19
2024
Q3
$19.8M Sell
122,305
-16,989
-12% -$2.71M 1.68% 17
2024
Q2
$20.4M Sell
139,294
-3,143
-2% -$467K 1.83% 14
2024
Q1
$22.5M Buy
142,437
+6,475
+5% +$1.03M 2.04% 11
2023
Q4
$21.3M Buy
135,962
+2,828
+2% +$434K 2.17% 7
2023
Q3
$20.7M Buy
133,134
+2,423
+2% +$400K 2.34% 6
2023
Q2
$21.6M Buy
130,711
+3,830
+3% +$618K 2.32% 5
2023
Q1
$19.7M Buy
126,881
+3,155
+3% +$509K 2.24% 5
2022
Q4
$21.9M Buy
123,726
+1,974
+2% +$341K 2.58% 5
2022
Q3
$19.9M Buy
121,752
+1,897
+2% +$321K 2.55% 6
2022
Q2
$21.3M Buy
119,855
+526
+0.4% +$93.7K 2.63% 4
2022
Q1
$21.1M Sell
119,329
-3,936
-3% -$670K 2.25% 5
2021
Q4
$21.1M Buy
123,265
+6,032
+5% +$988K 2.14% 5
2021
Q3
$18.9M Buy
117,233
+3,073
+3% +$524K 2.1% 6
2021
Q2
$18.8M Buy
114,160
+2,722
+2% +$451K 2.1% 6
2021
Q1
$18.3M Buy
111,438
+4,123
+4% +$667K 2.2% 5
2020
Q4
$16.9M Buy
107,315
+3,261
+3% +$481K 2.2% 7
2020
Q3
$15.5M Buy
104,054
+2,244
+2% +$332K 2.18% 8
2020
Q2
$14.3M Sell
101,810
-237
-0.2% -$34.5K 2.14% 8
2020
Q1
$13.4M Buy
102,047
+3,022
+3% +$429K 2.35% 8
2019
Q4
$14.4M Sell
99,025
-140
-0.1% -$19K 2.01% 8
2019
Q3
$12.8M Buy
99,165
+1,689
+2% +$223K 1.91% 9
2019
Q2
$13.6M Sell
97,476
-1,457
-1% -$202K 2.07% 8
2019
Q1
$13.8M Sell
98,933
-1,541
-2% -$206K 2.16% 6
2018
Q4
$13M Buy
100,474
+4,316
+4% +$602K 2.37% 4
2018
Q3
$12.9M Buy
96,158
+8,900
+10% +$1.18M 2.05% 6
2018
Q2
$10.6M Buy
87,258
+1,801
+2% +$225K 1.8% 10
2018
Q1
$11M Buy
85,457
+1,177
+1% +$159K 1.92% 7
2017
Q4
$11.8M Sell
84,280
-362
-0.4% -$50.4K 2% 7
2017
Q3
$11M Buy
84,642
+25,318
+43% +$3.36M 1.94% 7
2017
Q2
$7.85M Sell
59,324
-1,447
-2% -$185K 1.77% 9
2017
Q1
$7.57M Sell
60,771
-169
-0.3% -$20.2K 1.75% 10
2016
Q4
$7.02M Buy
60,940
+1,608
+3% +$186K 1.72% 12
2016
Q3
$7.01M Buy
59,332
+1,722
+3% +$209K 1.83% 9
2016
Q2
$6.99M Sell
57,610
-5
-0% -$568 1.88% 11
2016
Q1
$6.23M Sell
57,615
-5,587
-9% -$578K 1.75% 14
2015
Q4
$6.49M Buy
63,202
+1,721
+3% +$173K 1.77% 15
2015
Q3
$5.74M Sell
61,481
-775
-1% -$75K 1.58% 20
2015
Q2
$6.07M Buy
62,256
+3,866
+7% +$387K 1.5% 29
2015
Q1
$5.87M Buy
58,390
+4,157
+8% +$423K 1.45% 29
2014
Q4
$5.67M Buy
54,233
+1,326
+3% +$140K 1.41% 32
2014
Q3
$5.64M Sell
52,907
-685
-1% -$71K 1.38% 28
2014
Q2
$5.61M Sell
53,592
-42
-0.1% -$4.25K 1.36% 30
2014
Q1
$5.27M Buy
53,634
+2,365
+5% +$219K 1.41% 28
2013
Q4
$4.7M Buy
51,269
+1,610
+3% +$148K 1.3% 31
2013
Q3
$4.3M Sell
49,659
-971
-2% -$87.1K 1.34% 28
2013
Q2
$4.35M Buy
+50,630
New +$4.3M 1.46% 25

Other funds holding JNJ

Novare Capital Management's JNJ Position: Q1 2026 in Review

Novare Capital Management reduced its Johnson & Johnson (JNJ) stake by 4% in Q1 2026, selling an estimated $1.12M and leaving 115,100 shares worth $28.1M. The position accounts for 2.23% of the portfolio, ranked #11.

Novare Capital Management first reported a position in JNJ in Q2 2013 and has held it in 52 quarters since. 4,617 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Novare Capital Management held 115,100 shares of Johnson & Johnson worth $28.1M as of Q1 2026.
  • Novare Capital Management sold 4,807 Johnson & Johnson shares in Q1 2026, an estimated $1.12M.
  • Johnson & Johnson made up 2.23% of Novare Capital Management's portfolio in Q1 2026, its #11 holding.
  • Novare Capital Management first reported a position in Johnson & Johnson in Q2 2013 and has held it in 52 quarters since.
  • 4,617 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Novare Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.